Dextrose Injection Recalled Due to the Presence of Stainless Steel Particles

Key Takeaways:

• The US Food and Drug Administration (FDA) has issued a voluntary Class I recall for dextrose injection. The affected batch has been identified as Lot Y495066 (expires July 2027), containing 606 bags.
• The recall was initiated by Baxter Healthcare Corporation due to the presence of particulate matter, a quality issue that is likely to cause serious adverse health consequences or death.
• Dextrose is used to treat low blood sugar.

The FDA has issued a Class I recall for dextrose injection, affecting 606 bags. This product is being recalled by Baxter Healthcare Corporation based in Deerfield, Illinois. The recall was initiated on August 17, 2026, and received a Class I classification on September 15, 2026. A Class I classification means the use of this product is likely to cause serious adverse health consequences or death.

The recall was initiated after the firm discovered stainless steel particles in the product. This deficiency affects Lot Y495066, which will expire in July 2027. Baxter Healthcare Corporation sent out a public notice via letter; a press release was issued on August 25, 2026.

Dextrose is used to treat conditions related to low blood sugar, nutrition, and fluid balance by increasing levels of water and carbohydrates in the body. Pharmacists should identify and quarantine Lot Y495066, remove it from inventory, and coordinate with prescribers to provide an alternative supply.

Reference

FDA. Enforcement Report. September 16, 2026. Accessed September 16, 2026. https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=222187